Cover Image
Market Research Report
Product code 
1067093

Global Benign Prostatic Hyperplasia Therapeutics Market Size, Share & Industry Trends Analysis Report By Therapy (Mono Drug Therapy and Combination Drug Therapy), By Therapeutics Class, By Regional Outlook and Forecast, 2021 - 2027

Published: | KBV Research | 167 Pages | Delivery time: 1-2 business days

Price

Back to Top
Global Benign Prostatic Hyperplasia Therapeutics Market Size, Share & Industry Trends Analysis Report By Therapy (Mono Drug Therapy and Combination Drug Therapy), By Therapeutics Class, By Regional Outlook and Forecast, 2021 - 2027
Published: February 28, 2022
KBV Research
Content info: 167 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

The Global Benign Prostatic Hyperplasia Therapeutics Market size is expected to reach $7.4 billion by 2027, rising at a market growth of 4.6% CAGR during the forecast period.

Benign prostatic hyperplasia (BPH) is a benign swelling of the prostate gland that is not malignant. Benign prostatic hypertrophy or benign prostatic blockages are terms used to describe this ailment. One of the most common conditions in males over the age of 50 is prostate cancer. The hyperplastic alterations in the prostate tissue that result in prostatic enlargement generate BPH symptoms.

The size of men's prostate grows larger as they grow older. As the prostate gland grows larger, it presses against and compresses the urethra and causes thickening of the bladder's line. The obstruction increases urine outflow resistance and inhibits detrusor muscle responsiveness as a result of the obstruction. This disorder causes difficulty starting to urinate, a weak urine stream, inability to clear the urinary bladder, and increased pee frequency, which is most noticeable at night.

In men under the age of 40, signs and symptoms of prostate gland enlargement are uncommon. By the age of 60, around a third of men have moderate to severe symptoms, and by the age of 80, approximately half of men have them. Genetic background, diabetes as well as cardiovascular disease, and lifestyle are some factors that are responsible for the occurrence of benign prostate hyperplasia.

Moreover, the expiration of patents on major branded products has resulted in the development of various generic drugs, as well as collaboration among key players for the development of new BPH therapeutics for improved drug efficacy and safe therapy for prevailing drugs as well as impending new molecular entities, all of which contribute to the market's growth. The industry has been fueled further by a significant increase in healthcare expenditures around the world.

COVID-19 Impact Analysis

The COVID-19 pandemic caused severe losses to the world in terms of economy as well as healthcare. The pandemic caused a significant number of deaths as well as industrial closure. In addition, the COVID-19 outbreak also resulted in a negative influence on the market for treatments for benign prostatic hyperplasia. A significant number of hospitals and clinics around the world have been reconfigured to boost hospital capacity for COVID-19 patients. However, now that COVID-19 vaccines are accessible, several governments are trying to guarantee that life-saving medications and vaccines are supplied without interruption.

Elective procedures of benign pathology were recommended to be postponed until the burden on the healthcare system from COVID-19 lessened because hospitals would encounter a tremendous demand for resources to combat a likely increase in COVID-19 patients. Surgical operations such as TURP, HoLEP, ThuLEP, and PVP have to be postponed as a result.

Market Growth Factors:

Increasing prevalence of geriatric population

The inconvenience that is caused by benign prostate hyperplasia keeps increasing as the age of a man increases. In addition, the immunity of aged people is comparatively much lower than young people which make them more vulnerable toward hormonal disorders. BPH is hormonally dependent on testosterone and dihydrotestosterone (DHT) production and is considered a typical aspect of male aging. By the age of 60, approximately half of men have histopathologic BPH, and by the age of 85, 90% of men have it.

The evolving lifestyle of people across the world

With the increasing advancement and modernization, the lifestyle of people across the world is also evolving. The number of people that live a sedentary lifestyle is substantially increasing. The adoption of this lifestyle is likely to cause a significant rise in the number of people with obesity. Moreover, obesity is a major cause that facilitates the occurrence of benign prostatic hyperplasia. Due to the increased pressure on the abdominal area while seating, the prostate of a man undergoes extreme pressure and blockage in the blood vessels. This routine of people causes prostate enlargement or benign prostate hyperplasia.

Market Restraining Factors:

Side-effects post BPH medications

While both medicines and surgery can be used to treat BPH, both have severe side effects. 5-ARIs (5-alpha reductase inhibitors), Alpha-blockers, and other medication groups are routinely used to treat BPH. Orthostatic hypotension, dizziness, retrograde ejaculation, and rhinitis are all side effects of alpha-blockers. Some of these effects are more common in the elderly people, and they can lead to serious complications such as nausea, vomiting, and diarrhea.

Therapy Outlook

Based on the Therapy, the Benign prostatic hyperplasia therapeutic market is bifurcated into Mono drug therapy and Combination drug therapy. In 2020, the combination therapy recorded a substantial revenue share of the benign prostatic hyperplasia therapeutics market. The increased growth of this segment is attributed to multiple factors such as a wider range of antibiotics, colistin monotherapy having lesser effectiveness than beta-lactam monotherapy, and in vitro data demonstrating antibiotic combinations' synergy.

Therapeutics Class Outlook

Based on the Therapeutic class, the Benign prostatic hyperplasia therapeutic market is segmented into Alpha blockers, 5- alpha reductase inhibitors, Phosphodiesterase-5 inhibitors, and Others. In 2020, the 5- Alpha Reductase Inhibitors segment procured a substantial revenue share of the benign prostatic hyperplasia therapeutics market. Only men with confirmed prostate enlargement should use 5-alpha reductase inhibitors. 5-alpha-reductase inhibitors are a class of medications that are used to treat benign prostatic hyperplasia (enlarged prostate) and male pattern hair loss.

Regional Outlook

Based on the Region, the benign prostatic hyperplasia therapeutic market is analyzed across North America, Europe, APAC, LAMEA. In 2020, North America accounted for the largest revenue share of the benign prostatic hyperplasia therapeutics market. The increased growth of the market across this region is attributed to the robust healthcare infrastructure of the countries across the region. Countries like the US, Mexico, and Canada comprise established healthcare facilities. Moreover, the increased focus of the people toward their health is another major reason for the growth of the market across North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Astellas Pharma, Inc., Eli Lilly and Company, Allergan PLC (AbbVie), Merck Group (Merck Sharp & Dohme Corp.), Boehringer Ingelheim International GmbH, Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Pfizer, Inc., and Abbott Laboratories.

Scope of the Study

Market Segments covered in the Report:

By Therapy

  • Mono Drug Therapy
  • Combination Drug Therapy

By Therapeutics Class

  • Alpha Blockers
  • 5- alpha Reductase Inhibitors
  • Phosphodiesterase-5 Inhibitors
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • GlaxoSmithKline PLC (GSK)
  • Astellas Pharma, Inc.
  • Eli Lilly and Company
  • Allergan PLC (AbbVie)
  • Merck Group (Merck Sharp & Dohme Corp.)
  • Boehringer Ingelheim International GmbH
  • Teva Pharmaceuticals Industries Ltd.
  • Sanofi S.A.
  • Pfizer, Inc.
  • Abbott Laboratories

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Benign Prostatic Hyperplasia Therapeutics Market, by Therapy
    • 1.4.2 Global Benign Prostatic Hyperplasia Therapeutics Market, by Therapeutics Class
    • 1.4.3 Global Benign Prostatic Hyperplasia Therapeutics Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market composition and scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Global Benign Prostatic Hyperplasia Therapeutics Market by Therapy

  • 3.1 Global Mono Drug Therapy Market by Region
  • 3.2 Global Combination Drug Therapy Market by Region

Chapter 4. Global Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class

  • 4.1 Global Alpha Blockers Market by Region
  • 4.2 Global 5- alpha Reductase Inhibitors Market by Region
  • 4.3 Global Phosphodiesterase-5 Inhibitors Market by Region
  • 4.4 Global Others Market by Region

Chapter 5. Global Benign Prostatic Hyperplasia Therapeutics Market by Region

  • 5.1 North America Benign Prostatic Hyperplasia Therapeutics Market
    • 5.1.1 North America Benign Prostatic Hyperplasia Therapeutics Market by Therapy
      • 5.1.1.1 North America Mono Drug Therapy Market by Country
      • 5.1.1.2 North America Combination Drug Therapy Market by Country
    • 5.1.2 North America Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
      • 5.1.2.1 North America Alpha Blockers Market by Country
      • 5.1.2.2 North America 5- alpha Reductase Inhibitors Market by Country
      • 5.1.2.3 North America Phosphodiesterase-5 Inhibitors Market by Country
      • 5.1.2.4 North America Others Market by Country
    • 5.1.3 North America Benign Prostatic Hyperplasia Therapeutics Market by Country
      • 5.1.3.1 US Benign Prostatic Hyperplasia Therapeutics Market
        • 5.1.3.1.1 US Benign Prostatic Hyperplasia Therapeutics Market by Therapy
        • 5.1.3.1.2 US Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
      • 5.1.3.2 Canada Benign Prostatic Hyperplasia Therapeutics Market
        • 5.1.3.2.1 Canada Benign Prostatic Hyperplasia Therapeutics Market by Therapy
        • 5.1.3.2.2 Canada Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
      • 5.1.3.3 Mexico Benign Prostatic Hyperplasia Therapeutics Market
        • 5.1.3.3.1 Mexico Benign Prostatic Hyperplasia Therapeutics Market by Therapy
        • 5.1.3.3.2 Mexico Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
      • 5.1.3.4 Rest of North America Benign Prostatic Hyperplasia Therapeutics Market
        • 5.1.3.4.1 Rest of North America Benign Prostatic Hyperplasia Therapeutics Market by Therapy
        • 5.1.3.4.2 Rest of North America Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
  • 5.2 Europe Benign Prostatic Hyperplasia Therapeutics Market
    • 5.2.1 Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapy
      • 5.2.1.1 Europe Mono Drug Therapy Market by Country
      • 5.2.1.2 Europe Combination Drug Therapy Market by Country
    • 5.2.2 Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
      • 5.2.2.1 Europe Alpha Blockers Market by Country
      • 5.2.2.2 Europe 5- alpha Reductase Inhibitors Market by Country
      • 5.2.2.3 Europe Phosphodiesterase-5 Inhibitors Market by Country
      • 5.2.2.4 Europe Others Market by Country
    • 5.2.3 Europe Benign Prostatic Hyperplasia Therapeutics Market by Country
      • 5.2.3.1 Germany Benign Prostatic Hyperplasia Therapeutics Market
        • 5.2.3.1.1 Germany Benign Prostatic Hyperplasia Therapeutics Market by Therapy
        • 5.2.3.1.2 Germany Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
      • 5.2.3.2 UK Benign Prostatic Hyperplasia Therapeutics Market
        • 5.2.3.2.1 UK Benign Prostatic Hyperplasia Therapeutics Market by Therapy
        • 5.2.3.2.2 UK Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
      • 5.2.3.3 France Benign Prostatic Hyperplasia Therapeutics Market
        • 5.2.3.3.1 France Benign Prostatic Hyperplasia Therapeutics Market by Therapy
        • 5.2.3.3.2 France Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
      • 5.2.3.4 Russia Benign Prostatic Hyperplasia Therapeutics Market
        • 5.2.3.4.1 Russia Benign Prostatic Hyperplasia Therapeutics Market by Therapy
        • 5.2.3.4.2 Russia Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
      • 5.2.3.5 Spain Benign Prostatic Hyperplasia Therapeutics Market
        • 5.2.3.5.1 Spain Benign Prostatic Hyperplasia Therapeutics Market by Therapy
        • 5.2.3.5.2 Spain Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
      • 5.2.3.6 Italy Benign Prostatic Hyperplasia Therapeutics Market
        • 5.2.3.6.1 Italy Benign Prostatic Hyperplasia Therapeutics Market by Therapy
        • 5.2.3.6.2 Italy Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
      • 5.2.3.7 Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market
        • 5.2.3.7.1 Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapy
        • 5.2.3.7.2 Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
  • 5.3 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market
    • 5.3.1 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Therapy
      • 5.3.1.1 Asia Pacific Mono Drug Therapy Market by Country
      • 5.3.1.2 Asia Pacific Combination Drug Therapy Market by Country
    • 5.3.2 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
      • 5.3.2.1 Asia Pacific Alpha Blockers Market by Country
      • 5.3.2.2 Asia Pacific 5- alpha Reductase Inhibitors Market by Country
      • 5.3.2.3 Asia Pacific Phosphodiesterase-5 Inhibitors Market by Country
      • 5.3.2.4 Asia Pacific Others Market by Country
    • 5.3.3 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Country
      • 5.3.3.1 China Benign Prostatic Hyperplasia Therapeutics Market
        • 5.3.3.1.1 China Benign Prostatic Hyperplasia Therapeutics Market by Therapy
        • 5.3.3.1.2 China Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
      • 5.3.3.2 Japan Benign Prostatic Hyperplasia Therapeutics Market
        • 5.3.3.2.1 Japan Benign Prostatic Hyperplasia Therapeutics Market by Therapy
        • 5.3.3.2.2 Japan Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
      • 5.3.3.3 India Benign Prostatic Hyperplasia Therapeutics Market
        • 5.3.3.3.1 India Benign Prostatic Hyperplasia Therapeutics Market by Therapy
        • 5.3.3.3.2 India Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
      • 5.3.3.4 South Korea Benign Prostatic Hyperplasia Therapeutics Market
        • 5.3.3.4.1 South Korea Benign Prostatic Hyperplasia Therapeutics Market by Therapy
        • 5.3.3.4.2 South Korea Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
      • 5.3.3.5 Singapore Benign Prostatic Hyperplasia Therapeutics Market
        • 5.3.3.5.1 Singapore Benign Prostatic Hyperplasia Therapeutics Market by Therapy
        • 5.3.3.5.2 Singapore Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
      • 5.3.3.6 Malaysia Benign Prostatic Hyperplasia Therapeutics Market
        • 5.3.3.6.1 Malaysia Benign Prostatic Hyperplasia Therapeutics Market by Therapy
        • 5.3.3.6.2 Malaysia Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
      • 5.3.3.7 Rest of Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market
        • 5.3.3.7.1 Rest of Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Therapy
        • 5.3.3.7.2 Rest of Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
  • 5.4 LAMEA Benign Prostatic Hyperplasia Therapeutics Market
    • 5.4.1 LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Therapy
      • 5.4.1.1 LAMEA Mono Drug Therapy Market by Country
      • 5.4.1.2 LAMEA Combination Drug Therapy Market by Country
    • 5.4.2 LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
      • 5.4.2.1 LAMEA Alpha Blockers Market by Country
      • 5.4.2.2 LAMEA 5- alpha Reductase Inhibitors Market by Country
      • 5.4.2.3 LAMEA Phosphodiesterase-5 Inhibitors Market by Country
      • 5.4.2.4 LAMEA Others Market by Country
    • 5.4.3 LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Country
      • 5.4.3.1 Brazil Benign Prostatic Hyperplasia Therapeutics Market
        • 5.4.3.1.1 Brazil Benign Prostatic Hyperplasia Therapeutics Market by Therapy
        • 5.4.3.1.2 Brazil Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
      • 5.4.3.2 Argentina Benign Prostatic Hyperplasia Therapeutics Market
        • 5.4.3.2.1 Argentina Benign Prostatic Hyperplasia Therapeutics Market by Therapy
        • 5.4.3.2.2 Argentina Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
      • 5.4.3.3 UAE Benign Prostatic Hyperplasia Therapeutics Market
        • 5.4.3.3.1 UAE Benign Prostatic Hyperplasia Therapeutics Market by Therapy
        • 5.4.3.3.2 UAE Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
      • 5.4.3.4 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Market
        • 5.4.3.4.1 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Market by Therapy
        • 5.4.3.4.2 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
      • 5.4.3.5 South Africa Benign Prostatic Hyperplasia Therapeutics Market
        • 5.4.3.5.1 South Africa Benign Prostatic Hyperplasia Therapeutics Market by Therapy
        • 5.4.3.5.2 South Africa Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
      • 5.4.3.6 Nigeria Benign Prostatic Hyperplasia Therapeutics Market
        • 5.4.3.6.1 Nigeria Benign Prostatic Hyperplasia Therapeutics Market by Therapy
        • 5.4.3.6.2 Nigeria Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
      • 5.4.3.7 Rest of LAMEA Benign Prostatic Hyperplasia Therapeutics Market
        • 5.4.3.7.1 Rest of LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Therapy
        • 5.4.3.7.2 Rest of LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class

Chapter 6. Company Profiles

  • 6.1 GlaxoSmithKline PLC (GSK)
    • 6.1.1 Company Overview
    • 6.1.2 Financial Analysis
    • 6.1.3 Segmental and Regional Analysis
    • 6.1.4 Research & Development Expense
  • 6.2 Astellas Pharma, Inc.
    • 6.2.1 Company Overview
    • 6.2.2 Financial Analysis
    • 6.2.3 Regional Analysis
    • 6.2.4 Research & Development Expense
  • 6.3 Eli Lilly and Company
    • 6.3.1 Company Overview
    • 6.3.2 Financial Analysis
    • 6.3.3 Regional Analysis
    • 6.3.4 Research & Development Expense
  • 6.4 Allergan PLC (AbbVie)
    • 6.4.1 Company Overview
    • 6.4.2 Financial Analysis
    • 6.4.3 Regional Analysis
    • 6.4.4 Research & Development Expense
  • 6.5 Merck Group (Merck Sharp & Dohme Corp.)
    • 6.5.1 Company Overview
    • 6.5.2 Financial Analysis
    • 6.5.3 Segmental and Regional Analysis
    • 6.5.4 Research & Development Expense
  • 6.6 Boehringer Ingelheim International Gmbh
    • 6.6.1 Company Overview
    • 6.6.2 Financial Analysis
    • 6.6.3 Regional & Segmental Analysis
    • 6.6.4 Research & Development Expenses
  • 6.7 Teva Pharmaceutical Industries Ltd.
    • 6.7.1 Company Overview
    • 6.7.2 Financial Analysis
    • 6.7.3 Regional Analysis
    • 6.7.4 Research & Development Expenses
  • 6.8 Sanofi S.A.
    • 6.8.1 Company Overview
    • 6.8.2 Financial Analysis
    • 6.8.3 Segmental and Regional Analysis
    • 6.8.4 Research & Development Expense
  • 6.9 Pfizer, Inc.
    • 6.9.1 Company Overview
    • 6.9.2 Financial Analysis
    • 6.9.3 Regional Analysis
    • 6.9.4 Research & Development Expense
  • 6.10. Abbott Laboratories
    • 6.10.1 Company Overview
    • 6.10.2 Financial Analysis
    • 6.10.3 Segmental and Regional Analysis
    • 6.10.4 Research & Development Expense

LIST OF TABLES

  • TABLE 1 Global Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
  • TABLE 2 Global Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
  • TABLE 3 Global Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
  • TABLE 4 Global Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
  • TABLE 5 Global Mono Drug Therapy Market by Region, 2017 - 2020, USD Million
  • TABLE 6 Global Mono Drug Therapy Market by Region, 2021 - 2027, USD Million
  • TABLE 7 Global Combination Drug Therapy Market by Region, 2017 - 2020, USD Million
  • TABLE 8 Global Combination Drug Therapy Market by Region, 2021 - 2027, USD Million
  • TABLE 9 Global Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
  • TABLE 10 Global Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
  • TABLE 11 Global Alpha Blockers Market by Region, 2017 - 2020, USD Million
  • TABLE 12 Global Alpha Blockers Market by Region, 2021 - 2027, USD Million
  • TABLE 13 Global 5- alpha Reductase Inhibitors Market by Region, 2017 - 2020, USD Million
  • TABLE 14 Global 5- alpha Reductase Inhibitors Market by Region, 2021 - 2027, USD Million
  • TABLE 15 Global Phosphodiesterase-5 Inhibitors Market by Region, 2017 - 2020, USD Million
  • TABLE 16 Global Phosphodiesterase-5 Inhibitors Market by Region, 2021 - 2027, USD Million
  • TABLE 17 Global Others Market by Region, 2017 - 2020, USD Million
  • TABLE 18 Global Others Market by Region, 2021 - 2027, USD Million
  • TABLE 19 Global Benign Prostatic Hyperplasia Therapeutics Market by Region, 2017 - 2020, USD Million
  • TABLE 20 Global Benign Prostatic Hyperplasia Therapeutics Market by Region, 2021 - 2027, USD Million
  • TABLE 21 North America Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
  • TABLE 22 North America Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
  • TABLE 23 North America Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
  • TABLE 24 North America Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
  • TABLE 25 North America Mono Drug Therapy Market by Country, 2017 - 2020, USD Million
  • TABLE 26 North America Mono Drug Therapy Market by Country, 2021 - 2027, USD Million
  • TABLE 27 North America Combination Drug Therapy Market by Country, 2017 - 2020, USD Million
  • TABLE 28 North America Combination Drug Therapy Market by Country, 2021 - 2027, USD Million
  • TABLE 29 North America Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
  • TABLE 30 North America Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
  • TABLE 31 North America Alpha Blockers Market by Country, 2017 - 2020, USD Million
  • TABLE 32 North America Alpha Blockers Market by Country, 2021 - 2027, USD Million
  • TABLE 33 North America 5- alpha Reductase Inhibitors Market by Country, 2017 - 2020, USD Million
  • TABLE 34 North America 5- alpha Reductase Inhibitors Market by Country, 2021 - 2027, USD Million
  • TABLE 35 North America Phosphodiesterase-5 Inhibitors Market by Country, 2017 - 2020, USD Million
  • TABLE 36 North America Phosphodiesterase-5 Inhibitors Market by Country, 2021 - 2027, USD Million
  • TABLE 37 North America Others Market by Country, 2017 - 2020, USD Million
  • TABLE 38 North America Others Market by Country, 2021 - 2027, USD Million
  • TABLE 39 North America Benign Prostatic Hyperplasia Therapeutics Market by Country, 2017 - 2020, USD Million
  • TABLE 40 North America Benign Prostatic Hyperplasia Therapeutics Market by Country, 2021 - 2027, USD Million
  • TABLE 41 US Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
  • TABLE 42 US Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
  • TABLE 43 US Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
  • TABLE 44 US Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
  • TABLE 45 US Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
  • TABLE 46 US Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
  • TABLE 47 Canada Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
  • TABLE 48 Canada Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
  • TABLE 49 Canada Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
  • TABLE 50 Canada Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
  • TABLE 51 Canada Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
  • TABLE 52 Canada Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
  • TABLE 53 Mexico Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
  • TABLE 54 Mexico Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
  • TABLE 55 Mexico Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
  • TABLE 56 Mexico Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
  • TABLE 57 Mexico Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
  • TABLE 58 Mexico Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
  • TABLE 59 Rest of North America Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
  • TABLE 60 Rest of North America Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
  • TABLE 61 Rest of North America Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
  • TABLE 62 Rest of North America Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
  • TABLE 63 Rest of North America Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
  • TABLE 64 Rest of North America Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
  • TABLE 65 Europe Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
  • TABLE 66 Europe Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
  • TABLE 67 Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
  • TABLE 68 Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
  • TABLE 69 Europe Mono Drug Therapy Market by Country, 2017 - 2020, USD Million
  • TABLE 70 Europe Mono Drug Therapy Market by Country, 2021 - 2027, USD Million
  • TABLE 71 Europe Combination Drug Therapy Market by Country, 2017 - 2020, USD Million
  • TABLE 72 Europe Combination Drug Therapy Market by Country, 2021 - 2027, USD Million
  • TABLE 73 Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
  • TABLE 74 Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
  • TABLE 75 Europe Alpha Blockers Market by Country, 2017 - 2020, USD Million
  • TABLE 76 Europe Alpha Blockers Market by Country, 2021 - 2027, USD Million
  • TABLE 77 Europe 5- alpha Reductase Inhibitors Market by Country, 2017 - 2020, USD Million
  • TABLE 78 Europe 5- alpha Reductase Inhibitors Market by Country, 2021 - 2027, USD Million
  • TABLE 79 Europe Phosphodiesterase-5 Inhibitors Market by Country, 2017 - 2020, USD Million
  • TABLE 80 Europe Phosphodiesterase-5 Inhibitors Market by Country, 2021 - 2027, USD Million
  • TABLE 81 Europe Others Market by Country, 2017 - 2020, USD Million
  • TABLE 82 Europe Others Market by Country, 2021 - 2027, USD Million
  • TABLE 83 Europe Benign Prostatic Hyperplasia Therapeutics Market by Country, 2017 - 2020, USD Million
  • TABLE 84 Europe Benign Prostatic Hyperplasia Therapeutics Market by Country, 2021 - 2027, USD Million
  • TABLE 85 Germany Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
  • TABLE 86 Germany Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
  • TABLE 87 Germany Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
  • TABLE 88 Germany Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
  • TABLE 89 Germany Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
  • TABLE 90 Germany Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
  • TABLE 91 UK Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
  • TABLE 92 UK Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
  • TABLE 93 UK Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
  • TABLE 94 UK Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
  • TABLE 95 UK Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
  • TABLE 96 UK Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
  • TABLE 97 France Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
  • TABLE 98 France Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
  • TABLE 99 France Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
  • TABLE 100 France Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
  • TABLE 101 France Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
  • TABLE 102 France Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
  • TABLE 103 Russia Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
  • TABLE 104 Russia Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
  • TABLE 105 Russia Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
  • TABLE 106 Russia Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
  • TABLE 107 Russia Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
  • TABLE 108 Russia Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
  • TABLE 109 Spain Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
  • TABLE 110 Spain Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
  • TABLE 111 Spain Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
  • TABLE 112 Spain Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
  • TABLE 113 Spain Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
  • TABLE 114 Spain Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
  • TABLE 115 Italy Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
  • TABLE 116 Italy Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
  • TABLE 117 Italy Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
  • TABLE 118 Italy Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
  • TABLE 119 Italy Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
  • TABLE 120 Italy Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
  • TABLE 121 Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
  • TABLE 122 Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
  • TABLE 123 Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
  • TABLE 124 Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
  • TABLE 125 Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
  • TABLE 126 Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
  • TABLE 127 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
  • TABLE 128 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
  • TABLE 129 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
  • TABLE 130 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
  • TABLE 131 Asia Pacific Mono Drug Therapy Market by Country, 2017 - 2020, USD Million
  • TABLE 132 Asia Pacific Mono Drug Therapy Market by Country, 2021 - 2027, USD Million
  • TABLE 133 Asia Pacific Combination Drug Therapy Market by Country, 2017 - 2020, USD Million
  • TABLE 134 Asia Pacific Combination Drug Therapy Market by Country, 2021 - 2027, USD Million
  • TABLE 135 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
  • TABLE 136 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
  • TABLE 137 Asia Pacific Alpha Blockers Market by Country, 2017 - 2020, USD Million
  • TABLE 138 Asia Pacific Alpha Blockers Market by Country, 2021 - 2027, USD Million
  • TABLE 139 Asia Pacific 5- alpha Reductase Inhibitors Market by Country, 2017 - 2020, USD Million
  • TABLE 140 Asia Pacific 5- alpha Reductase Inhibitors Market by Country, 2021 - 2027, USD Million
  • TABLE 141 Asia Pacific Phosphodiesterase-5 Inhibitors Market by Country, 2017 - 2020, USD Million
  • TABLE 142 Asia Pacific Phosphodiesterase-5 Inhibitors Market by Country, 2021 - 2027, USD Million
  • TABLE 143 Asia Pacific Others Market by Country, 2017 - 2020, USD Million
  • TABLE 144 Asia Pacific Others Market by Country, 2021 - 2027, USD Million
  • TABLE 145 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Country, 2017 - 2020, USD Million
  • TABLE 146 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Country, 2021 - 2027, USD Million
  • TABLE 147 China Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
  • TABLE 148 China Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
  • TABLE 149 China Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
  • TABLE 150 China Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
  • TABLE 151 China Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
  • TABLE 152 China Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
  • TABLE 153 Japan Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
  • TABLE 154 Japan Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
  • TABLE 155 Japan Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
  • TABLE 156 Japan Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
  • TABLE 157 Japan Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
  • TABLE 158 Japan Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
  • TABLE 159 India Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
  • TABLE 160 India Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
  • TABLE 161 India Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
  • TABLE 162 India Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
  • TABLE 163 India Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
  • TABLE 164 India Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
  • TABLE 165 South Korea Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
  • TABLE 166 South Korea Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
  • TABLE 167 South Korea Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
  • TABLE 168 South Korea Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
  • TABLE 169 South Korea Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
  • TABLE 170 South Korea Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
  • TABLE 171 Singapore Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
  • TABLE 172 Singapore Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
  • TABLE 173 Singapore Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
  • TABLE 174 Singapore Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
  • TABLE 175 Singapore Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
  • TABLE 176 Singapore Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
  • TABLE 177 Malaysia Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
  • TABLE 178 Malaysia Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
  • TABLE 179 Malaysia Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
  • TABLE 180 Malaysia Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
  • TABLE 181 Malaysia Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
  • TABLE 182 Malaysia Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
  • TABLE 183 Rest of Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
  • TABLE 184 Rest of Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
  • TABLE 185 Rest of Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
  • TABLE 186 Rest of Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
  • TABLE 187 Rest of Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
  • TABLE 188 Rest of Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
  • TABLE 189 LAMEA Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
  • TABLE 190 LAMEA Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
  • TABLE 191 LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
  • TABLE 192 LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
  • TABLE 193 LAMEA Mono Drug Therapy Market by Country, 2017 - 2020, USD Million
  • TABLE 194 LAMEA Mono Drug Therapy Market by Country, 2021 - 2027, USD Million
  • TABLE 195 LAMEA Combination Drug Therapy Market by Country, 2017 - 2020, USD Million
  • TABLE 196 LAMEA Combination Drug Therapy Market by Country, 2021 - 2027, USD Million
  • TABLE 197 LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
  • TABLE 198 LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
  • TABLE 199 LAMEA Alpha Blockers Market by Country, 2017 - 2020, USD Million
  • TABLE 200 LAMEA Alpha Blockers Market by Country, 2021 - 2027, USD Million
  • TABLE 201 LAMEA 5- alpha Reductase Inhibitors Market by Country, 2017 - 2020, USD Million
  • TABLE 202 LAMEA 5- alpha Reductase Inhibitors Market by Country, 2021 - 2027, USD Million
  • TABLE 203 LAMEA Phosphodiesterase-5 Inhibitors Market by Country, 2017 - 2020, USD Million
  • TABLE 204 LAMEA Phosphodiesterase-5 Inhibitors Market by Country, 2021 - 2027, USD Million
  • TABLE 205 LAMEA Others Market by Country, 2017 - 2020, USD Million
  • TABLE 206 LAMEA Others Market by Country, 2021 - 2027, USD Million
  • TABLE 207 LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Country, 2017 - 2020, USD Million
  • TABLE 208 LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Country, 2021 - 2027, USD Million
  • TABLE 209 Brazil Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
  • TABLE 210 Brazil Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
  • TABLE 211 Brazil Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
  • TABLE 212 Brazil Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
  • TABLE 213 Brazil Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
  • TABLE 214 Brazil Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
  • TABLE 215 Argentina Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
  • TABLE 216 Argentina Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
  • TABLE 217 Argentina Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
  • TABLE 218 Argentina Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
  • TABLE 219 Argentina Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
  • TABLE 220 Argentina Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
  • TABLE 221 UAE Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
  • TABLE 222 UAE Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
  • TABLE 223 UAE Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
  • TABLE 224 UAE Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
  • TABLE 225 UAE Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
  • TABLE 226 UAE Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
  • TABLE 227 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
  • TABLE 228 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
  • TABLE 229 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
  • TABLE 230 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
  • TABLE 231 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
  • TABLE 232 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
  • TABLE 233 South Africa Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
  • TABLE 234 South Africa Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
  • TABLE 235 South Africa Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
  • TABLE 236 South Africa Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
  • TABLE 237 South Africa Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
  • TABLE 238 South Africa Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
  • TABLE 239 Nigeria Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
  • TABLE 240 Nigeria Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
  • TABLE 241 Nigeria Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
  • TABLE 242 Nigeria Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
  • TABLE 243 Nigeria Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
  • TABLE 244 Nigeria Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
  • TABLE 245 Rest of LAMEA Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
  • TABLE 246 Rest of LAMEA Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
  • TABLE 247 Rest of LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
  • TABLE 248 Rest of LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
  • TABLE 249 Rest of LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
  • TABLE 250 Rest of LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
  • TABLE 251 Key Information - GlaxoSmithKline PLC (GSK)
  • TABLE 252 key information - Astellas Pharma, Inc.
  • TABLE 253 Key Information - Eli Lilly and Company
  • TABLE 254 Key Information - Allergan PLC
  • TABLE 255 key Information - Merck Group
  • TABLE 256 Key Information - Boehringer Ingelheim International GmbH
  • TABLE 257 Key Information - Teva Pharmaceuticals Industries Ltd.
  • TABLE 258 Key Information - Sanofi S.A.
  • TABLE 259 Key Information - Pfizer, Inc.
  • TABLE 260 Key Information - Abbott Laboratories

List of Figures

  • FIG 1 Methodology for the research